{"version":"company-facts.v1","source":"https://secwatch.observer","generated_at":"2026-06-05T06:43:30.016969+00:00","company":{"ticker":"PMDI","cik":806517,"company_name":"PSYCHEMEDICS CORP"},"pagination":{"limit":100,"returned":2,"next_cursor":null},"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer","facts":[{"fact_type":"earnings_release","fact_key":"10c74eb118f012a99a9551bf01e821e0c3617cee","cik":806517,"ticker":"PMDI","company_name":"PSYCHEMEDICS CORP","filed_at":"2024-05-14T23:59:59+00:00","payload":{"eps_text":"$0.12 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"$0.7 million","period_text":"the first quarter ended March 31, 2024","report_date":"2024-05-14","result_type":"reported_results","revenue_text":"$5.4 million"},"claim":"PSYCHEMEDICS CORP reported the first quarter ended March 31, 2024 results: revenue $5.4 million, net income $0.7 million, EPS $0.12 per share.","evidence_excerpt":"The Company’s revenue for the quarter ended March 31, 2024, was $5.4 million versus $5.9 million for the quarter ended March 31, 2023, a decrease of 9%. Net loss for the quarter was $0.7 million, or $0.12 per share, compared to a net loss of $0.4 million, or $.07 per share, for the comparable quarter last year.","confidence":0.95,"filing_url":"https://secwatch.observer/filing/0001171843-24-002873","anchor_url":"https://secwatch.observer/filing/0001171843-24-002873#claim-10c74eb118f012a99a9551bf01e821e0c3617cee","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/806517/000117184324002873/0001171843-24-002873-index.htm"},{"fact_type":"earnings_release","fact_key":"ba33cf2d6ed8986598eb2524fe2f8cec8351bf55","cik":806517,"ticker":"PMDI","company_name":"PSYCHEMEDICS CORP","filed_at":"2024-03-28T23:59:59+00:00","payload":{"eps_text":"$0.72 per share","guidance_signal":"none","item_codes_triggered":["2.02"],"net_income_text":"net loss of approximately $4.2 million","period_text":"the year ended December 31, 2023","report_date":"2024-03-28","result_type":"reported_results","revenue_text":"$22.1 million"},"claim":"PSYCHEMEDICS CORP reported the year ended December 31, 2023 results: revenue $22.1 million, net income net loss of approximately $4.2 million, EPS $0.72 per share.","evidence_excerpt":"but also solidify our position as the leader in the industry,” added Shannon Shoemaker, Chief Revenue Officer. The Company's revenue for the year ended December 31, 2023, was $22.1 million versus $25.2 million for the prior year, a decrease of 12%. As of December 31, 2023, the Company had cash and cash equivalents of approximately $2.0 million, compared with","confidence":1.0,"filing_url":"https://secwatch.observer/filing/0001171843-24-001669","anchor_url":"https://secwatch.observer/filing/0001171843-24-001669#claim-ba33cf2d6ed8986598eb2524fe2f8cec8351bf55","edgar_index_url":"https://www.sec.gov/Archives/edgar/data/806517/000117184324001669/0001171843-24-001669-index.htm"}]}